BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Influenza
,
Hippocampus
,
Metabolism of nitric oxide
,
Doxorubicin
,
rs6983267
,
KLK3
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
nvp tae684
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Anaplastic lymphoma kinase inhibitor NVP‑TAE684 suppresses the proliferation of human pancreatic ade…
NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (P…
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and i…
Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic fact…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for nvp tae684
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ